Yen Yun 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jul 9, 2025
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2025-06-30+10,000→ 10,000 totalExercise: $0.91From: 2025-09-30Exp: 2030-06-30→ Common (10,000 underlying) - Award
Options to Purchase Common Stock
2025-06-30+11,632→ 11,632 totalExercise: $0.91From: 2025-06-30Exp: 2030-06-30→ Common (11,652 underlying)
Holdings
- 5,786
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,786 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 8,777
Options to Purchase Common Stock
Exercise: $1.21From: 2025-03-31Exp: 2030-03-31→ Common (8,777 underlying) - 4,545
Options to Purchase Common Stock
Exercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,545 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 4,527
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,527 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 5,263(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2020-11-30Exp: 2025-11-30→ Common (5,263 underlying) - 3,333
Options to Purchase Common Stock
Exercise: $16.80From: 2018-08-04Exp: 2023-08-04→ Common (3,333 underlying)
Footnotes (2)
- [F1]Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
- [F2]Effective June 30, 2025 the reporting person was granted stock options in aggregate of 11,632 vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.